| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Trade names | Combivent, Duoneb, Breva, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601063 |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Ipratropium bromide/salbutamol, sold under the brand nameCombivent among others, is acombination medication used to treatchronic obstructive pulmonary disease (COPD).[1][4][5] It containsipratropium (ananticholinergic) andsalbutamol (albuterol, aβ2-adrenergic agonist).[1]
Common side effects include sore throat, muscle cramps, and nausea.[1] Other side effects may includebronchospasm,allergic reactions, andupper respiratory tract infections.[1] Safety inpregnancy is unclear.[6][1]
The combination was approved for medical use in the United States in 1996.[7] It is available as ageneric medication.[4] In 2023, it was the 181st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9]
Ipratropium bromide/salbutamol can be used for the treatment of COPD[5] and asthma.[10]
Since Combivent contains achlorofluorocarbon-based propellant, that propellant was discontinued in 2013 in the United States and other countries. This is because chlorofluorocarbons are attributed todepletion of the ozone layer.[11]
